262 related articles for article (PubMed ID: 32861983)
1. Can 'floating' predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression.
Acevedo-Diaz EE; Cavanaugh GW; Greenstein D; Kraus C; Kadriu B; Park L; Zarate CA
J Psychiatr Res; 2020 Nov; 130():280-285. PubMed ID: 32861983
[TBL] [Abstract][Full Text] [Related]
2. The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression.
Lineham A; Avila-Quintero VJ; Bloch MH; Dwyer J
J Child Adolesc Psychopharmacol; 2023 Feb; 33(1):20-26. PubMed ID: 36799961
[No Abstract] [Full Text] [Related]
3. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression.
Acevedo-Diaz EE; Cavanaugh GW; Greenstein D; Kraus C; Kadriu B; Zarate CA; Park LT
J Affect Disord; 2020 Feb; 263():568-575. PubMed ID: 31791675
[TBL] [Abstract][Full Text] [Related]
5. Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression.
Niciu MJ; Shovestul BJ; Jaso BA; Farmer C; Luckenbaugh DA; Brutsche NE; Park LT; Ballard ED; Zarate CA
J Affect Disord; 2018 May; 232():310-315. PubMed ID: 29501990
[TBL] [Abstract][Full Text] [Related]
6. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
Phillips JL; Norris S; Talbot J; Birmingham M; Hatchard T; Ortiz A; Owoeye O; Batten LA; Blier P
Am J Psychiatry; 2019 May; 176(5):401-409. PubMed ID: 30922101
[TBL] [Abstract][Full Text] [Related]
7. Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression.
Luckenbaugh DA; Ibrahim L; Brutsche N; Franco-Chaves J; Mathews D; Marquardt CA; Cassarly C; Zarate CA
Bipolar Disord; 2012 Dec; 14(8):880-7. PubMed ID: 22978511
[TBL] [Abstract][Full Text] [Related]
8. A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation.
Su TP; Li CT; Lin WC; Wu HJ; Tsai SJ; Bai YM; Mao WC; Tu PC; Chen LF; Li WC; Chen MH
Int J Neuropsychopharmacol; 2023 May; 26(5):331-339. PubMed ID: 36966411
[TBL] [Abstract][Full Text] [Related]
9. Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression.
Xu AJ; Niciu MJ; Lundin NB; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Machado-Vieira R; Zarate CA
Neural Plast; 2015; 2015():858251. PubMed ID: 26137324
[TBL] [Abstract][Full Text] [Related]
10. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA
Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539512
[TBL] [Abstract][Full Text] [Related]
11. The effects of ketamine on typical and atypical depressive symptoms.
Park LT; Luckenbaugh DA; Pennybaker SJ; Hopkins MA; Henter ID; Lener MS; Kadriu B; Ballard ED; Zarate CA
Acta Psychiatr Scand; 2020 Nov; 142(5):394-401. PubMed ID: 32677051
[TBL] [Abstract][Full Text] [Related]
12. Experiences of Awe Mediate Ketamine's Antidepressant Effects: Findings From a Randomized Controlled Trial in Treatment-Resistant Depression.
Aepfelbacher J; Panny B; Price RB
Biol Psychiatry Glob Open Sci; 2024 Jul; 4(4):100316. PubMed ID: 38726038
[TBL] [Abstract][Full Text] [Related]
13. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV
Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095
[TBL] [Abstract][Full Text] [Related]
14. Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant.
Hudgens S; Floden L; Blackowicz M; Jamieson C; Popova V; Fedgchin M; Drevets WC; Cooper K; Lane R; Singh J
J Affect Disord; 2021 Feb; 281():767-775. PubMed ID: 33261932
[TBL] [Abstract][Full Text] [Related]
15. Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression.
Jesus-Nunes AP; Leal GC; Correia-Melo FS; Vieira F; Mello RP; Caliman-Fontes AT; Echegaray MVF; Marback RF; Guerreiro-Costa LNF; Souza-Marques B; Santos-Lima C; Souza LS; Bandeira ID; Kapczinski F; Lacerda ALT; Quarantini LC
Hum Psychopharmacol; 2022 Jul; 37(4):e2836. PubMed ID: 35179810
[TBL] [Abstract][Full Text] [Related]
16. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
[TBL] [Abstract][Full Text] [Related]
17. Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: A randomized, double-blind control study.
Chen MH; Li CT; Lin WC; Hong CJ; Tu PC; Bai YM; Cheng CM; Su TP
Psychiatry Res; 2018 Nov; 269():207-211. PubMed ID: 30153598
[TBL] [Abstract][Full Text] [Related]
18. Ketamine administration in depressive disorders: a systematic review and meta-analysis.
Fond G; Loundou A; Rabu C; Macgregor A; Lançon C; Brittner M; Micoulaud-Franchi JA; Richieri R; Courtet P; Abbar M; Roger M; Leboyer M; Boyer L
Psychopharmacology (Berl); 2014 Sep; 231(18):3663-76. PubMed ID: 25038867
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
[TBL] [Abstract][Full Text] [Related]
20. Disentangling the association of depression on the anti-fatigue effects of ketamine.
Saligan LN; Farmer C; Ballard ED; Kadriu B; Zarate CA
J Affect Disord; 2019 Feb; 244():42-45. PubMed ID: 30312839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
